Am J Transplant, Volume 22, Suppl 3 Archives - Page 141 of 190 - ATC Abstracts

2022 American Transplant Congress
Reduced Enterohepatic Recirculation of Mycophenolate and Lower Blood Concentrations Are Associated with the Stool Bacterial Microbiome
P. A. Jacobson¹, A. Saqr¹, B. Carlson¹, C. Staley², A. Rashidi³, S. Holtan³, M. Al-Kofahi¹, T. Kaiser², M. MacMillan⁴, J. Young⁵, N. El Jurdi³, D. Weisdorf³, A. Khoruts⁶
¹Univ of MN, College of Pharmacy, Minneapolis, MN, ²Univ of MN, Dept of Surgery, Minneapolis, MN, ³Univ of MN, Divison of Heme/Onc Transplant, Minneapolis, MN, ⁴Univ of MN, Pediatric Heme/Onc Transplant, Minneapolis, MN, ⁵Univ of MN, Divison of Infectious Diseases, Minneapolis, MN, ⁶Univ of MN, Division of Gastroenterology, Hepatology and Nutrition, Minneapolis, MN
*Purpose: Mycophenolate mofetil (MMF) is an important immunosuppressant used after allogeneic hematopoietic cell transplant (HCT). Blood concentrations of mycophenolic acid (MPA) are highly variable and…
2022 American Transplant Congress
Blood Transcriptomes of Covid-19 Infected Kidney Recipients Demonstrate Frequent and Persistent Sars-cov-2 Virome Gene Expression
Z. Sun¹, M. M. Rana², A. C. Reghuvaran³, Y. A. Azzi⁴, G. Carrara⁵, S. Hartzell⁶, S. Kulkarni³, W. Zhang⁶, K. Banu³, P. Heeger⁶, E. Akalin⁴, P. Cravedi⁶, Z. Zhang⁷, M. C. Menon³
¹Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, ²Infectious Disease Director, Icahn School of Medicine at Mount Sinai, New York, NY, ³Nephrology, Yale University, New Haven, CT, ⁴Nephrology, Montefiore Medical Center, New York, NY, ⁵Clinical Research Coordinator, Icahn School of Medicine at Mount Sinai, New York, NY, ⁶Icahn School of Medicine at Mount Sinai, New York, NY, ⁷Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
*Purpose: Kidney transplant recipients (KTRs) have poor outcomes vs non-KTRs with acute COVID-19. To provide insight into management of immunosuppression during acute COVID-19, we studied…
2022 American Transplant Congress
Management of Hepatitis B Positive Donors in Liver Transplant
M. Tilley¹, T. A. Sparkman², K. Gutierrez²
¹Pharmacy, UAB, Birmingham, AL, ²UAB, Birmingham, AL
*Purpose: In an effort to expand the pool of solid organ transplant donors, patients with end stage liver disease may receive an organ from a…
2022 American Transplant Congress
B and Plasma Cell Populations Drive Chronic Rejection After Lung Transplantation
M. Bueno¹, N. F. Smirnova², K. Riemondy³, P. Suresh¹, M. Brown¹, X. Wang¹, S. Collins⁴, J. Sembrat¹, M. Koenigshoff¹, M. Snyder¹, J. McDyer¹, O. Eickelberg¹
¹Pulmonary and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, ²I2MC, INSERM UMR1297, Toulouse, France, ³Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, CO, ⁴Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, CO
*Purpose: Chronic lung allograft dysfunction (CLAD) remains the major determinant of morbidity and mortality post-lung transplantation (LTx). Bronchiolitis obliterans syndrome (BOS) is the most prevalent…
2022 American Transplant Congress
Seroprevalence of MMR and Varicella (MMRV) in Solid Organ Transplant Candidates and Seroresponse to MMRV Vaccinations
H. Javaid¹, R. Hasbun¹, A. DeGolovine², S. Jyothula³, V. Machicao⁴, J. Bynon⁵, L. Ostrosky¹, M. Nigo¹
¹Division of Infectious Diseases, McGovern Medical School, University of Texas Health Science Center, Houston, TX, ²Div of Renal Disease, Univ of Texas Health Science Center, Houston, TX, ³Div of Advanced Heart Failure and Transplant Cardiology, Univ of Texas Health Science Center, Houston, TX, ⁴Div of Transplant Hepatology, Univ of Texas Health Science Center, Houston, TX, ⁵Div of Immunology and Organ Transplantation, Univ of Texas Health Science Center, Houston, TX
*Purpose: Updating live vaccines such as MMR and varicella (MMRV) is an important step in preparing patients during the pre-solid organ transplant (SOT) period. While…
2022 American Transplant Congress
Long-Term Follow Up of Solid Organ Transplantation Using Hepatitis C Virus Positive Donor for Hepatitis C Virus Negative Recipients
H. Sogawa¹, I. Lee², K. Okumura³, R. Bodin⁴, D. C. Wolf⁴, B. Partiula⁴, A. Dhand⁴, M. Kai⁵, S. Ohira⁵, R. Misawa¹, G. Veillette⁶, D. John¹, S. Nishida⁷, T. Diflo⁶
¹Division of Intra-abdominal Organ Transplant, Department of Surgery, Westchester Medical Center/ New York Medical College, Valhalla, NY, ²Department of Surgery, Westchester Medical Center/ New York Medical College, Valhalla, NY, ³Surgery, Westchester Medical Center/New York Medical College, Valhalla, NY, ⁴Department of Medicine, Westchester Medical Center/ New York Medical College, Valhalla, NY, ⁵Cardiothoracic Surgery, Westchester Medical Center/ New York Medical College, Valhalla, NY, ⁶Westchester Medical Center, Valhalla, NY, ⁷Westchester Medical Center/ New York Medical College, Valhalla, NY
*Purpose: To determine the effects of transplanting an HCV + solid organ to an uninfected patient who is on the transplant waiting list. Outcomes include…
2022 American Transplant Congress
Transplantation of Hepatitis C Viremic Donor Organs to Hepatitis C Nonviremic Recipients: A Retrospective Review
M. Leick, M. Blaha, M. Henry
Nebraska Medicine, Omaha, NE
*Purpose: The advent of combination direct-acting antiviral (DAA) agents has improved the ability to treat hepatitis C virus (HCV) infections. As a result, utilization of…
2022 American Transplant Congress
Hepatitis C Positive Kidney Transplant Into Hepatitis C Negative Recipients
R. Savilla¹, A. Ricketts¹, S. A. Deslich², S. Vaishnav¹, J. B. Africa¹, S. Nagaraju¹
¹Renal Transplant, Charleston Area Medical Center, Charleston, WV, ²Research Associate Senior, Health Services & Outcomes Rsc, Charleston Area Medical Center, Charleston, WV
*Purpose: Kidney transplantation is the treatment of choice in end stage renal disease (ESRD). In 2018, 5% to 8% of eligible adults died while on…
2022 American Transplant Congress
Risk for Loss of Hepatitis B Surface Antibody or Hepatitis B Reactivation in Kidney Transplant Recipients Receiving Lymphocyte Depleting Induction
K. Paplaczyk¹, C. Kane¹, M. Kapugi¹, K. Lang¹, K. Cunningham¹, C. D'Agostino¹, J. Boike²
¹Pharmacy, Northwestern Memorial Hospital, Chicago, IL, ²Transplant Hepatology, Northwestern Memorial Hospital, Chicago, IL
*Purpose: Although used in over 60% of kidney transplant recipients, the impact of lymphocyte depleting induction on hepatitis B surface antibody (HBsAb) and hepatitis B…
2022 American Transplant Congress
Donor-Derived Cell-Free DNA (dd-cfDNA) for Assessment of Response After Treatment of Allograft Rejection
R. Gohh¹, J. Klein², M. Jagadeesan³, V. Rao⁴, M. Weir⁵, H. Gilligan⁶, G. Shekhtman⁷, N. Agrawal⁸, Y. Fu⁹, E. Akalin¹⁰
¹Alpert School of Medicine, Brown University, Providence, RI, ²University of Kansas Medical Center, Kansas City, KS, ³George Washington School of Medicine, Washington, DC, ⁴Medical University of South Carolina, Charleston, SC, ⁵University of Maryland, Baltimore, MD, ⁶Massachusetts General Hospital, Boston, MA, ⁷CareDx Inc., Brisbane, CA, ⁸CareDx Inc, Brisbane, CA, ⁹CareDx, Brisbane, CA, ¹⁰Montefiore Medical Center, Bronx, NY
*Purpose: Surveillance of dd-cfDNA after therapy for rejection represents a promising strategy for monitoring post-treatment response. We assessed post-rejection kinetics of dd-cfDNA among kidney transplant…